RecruitingPhase 1NCT05885412
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Studying Inherited arrhythmogenic cardiomyopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rocket Pharmaceuticals Inc.
- Principal Investigator
- Barry Greenberg, MDUniversity of California, San Diego
- Intervention
- RP-A601(genetic)
- Enrollment
- 9 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (3)
- University of California, San Diego, La Jolla, California, United States
- Duke University, Durham, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05885412 on ClinicalTrials.govOther trials for Inherited arrhythmogenic cardiomyopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06922994Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)Centro Cardiologico Monzino
- RECRUITINGNCT06352307Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic CardiomyopathyFirst Affiliated Hospital Xi'an Jiaotong University
- RECRUITINGNCT06976606A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACMLexeo Therapeutics
- RECRUITINGNANCT06040242Arrhythmogenic Activity During Exercise in ARVC PatientsSwiss Federal Institute of Technology
- RECRUITINGNCT06409585Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis TransitionUniversity of Edinburgh
- RECRUITINGNANCT06311708Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)Tenaya Therapeutics
- RECRUITINGNCT04521790Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic ManagementScientific Institute San Raffaele
- RECRUITINGNCT06591260Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)Scientific Institute San Raffaele
See all trials for Inherited arrhythmogenic cardiomyopathy →